Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
BDRX moved a median of -0.42% 30 minutes after news, and -0.70% by the close. How BDRX actually reacts to news — the realized, point-in-time move the market made, measured across 492 labeled events over the last three years with zero look-ahead.
BDRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 448 |
| 30-min | -0.42% | 37% | 472 |
| 60-min | -0.98% | 38% | 478 |
| to close | -0.70% | 42% | 492 |
| Middle 50% of BDRX reactions | -2.90% to +1.02% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 492 |
Half of all Biodexa Pharmaceuticals plc - American Depositary Shares news events land between -2.90% and +1.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BDRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BDRX's baseline. Nothing else.
Recent BDRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Biodexa Pharmaceuticals For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | -0.34% | -3.35% | |
| Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP | Press release | GlobeNewswire | -5.54% | -16.00% | |
| Form 6-K Biodexa Pharmaceuticals For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | -3.85% | -11.50% | |
| Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight | Press release | PR Newswire | -0.96% | +4.37% | |
| Form EFFECT Biodexa Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -7.19% | -5.30% | |
| Form F-1 Biodexa Pharmaceuticals | SEC filing · Form F-1 | SEC EDGAR | -0.90% | +0.75% | |
| The Longview: Fireside Chat with Biodexa CEO Stephen Stamp | Press release | ACCESS Newswire | +0.26% | +0.98% | |
| Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds | Press release | GlobeNewswire | -0.92% | +2.31% | |
| Form 6-K Biodexa Pharmaceuticals For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | -0.92% | +2.31% | |
| Form 6-K Biodexa Pharmaceuticals For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +6.08% | -13.85% | |
| Interim results for the six months ended June 30, 2026 | Press release | GlobeNewswire | +6.08% | -13.85% | |
| Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP | Press release | GlobeNewswire | +1.50% | -5.26% | |
| Form EFFECT Biodexa Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +4.93% | |
| Form F-1/A Biodexa Pharmaceuticals | SEC filing · Form F-1 | SEC EDGAR | +3.91% | +15.63% | |
| Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France | Press release | GlobeNewswire | -0.66% | -1.03% | |
| Form 6-K Biodexa Pharmaceuticals For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | +3.91% | +15.63% | |
| Result of General Meeting | Press release | GlobeNewswire | +3.91% | +15.63% | |
| Form F-1 Biodexa Pharmaceuticals | SEC filing · Form F-1 | SEC EDGAR | +0.90% | -4.05% | |
| Form 6-K Biodexa Pharmaceuticals For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | — | -0.40% | |
| Form 6-K/A Biodexa Pharmaceuticals For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +7.91% | |
| Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants | Press release | GlobeNewswire | -7.09% | +3.19% | |
| Form 6-K Biodexa Pharmaceuticals For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -7.09% | +3.19% | |
| Result of Annual General Meeting | Press release | GlobeNewswire | +0.00% | +7.91% | |
| Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress | Press release | GlobeNewswire | -2.09% | -1.04% | |
| Form 6-K Biodexa Pharmaceuticals For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | — | +1.32% | |
| Postponement and Re-scheduling of Annual General Meeting | Press release | GlobeNewswire | — | +1.32% | |
| Biodexa issues letter to Shareholders | Press release | GlobeNewswire | -0.83% | -5.82% | |
| Form 6-K Biodexa Pharmaceuticals For: May 14 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.90% | |
| Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies | Press release | GlobeNewswire | +12.62% | -5.44% | |
| Form EFFECT Biodexa Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.34% | +1.31% | |
| Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients | Press release | Business Wire | +0.34% | +1.31% | |
| Form POS AM Biodexa Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | +1.74% | -8.72% | |
| Form 20-F Biodexa Pharmaceuticals For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +1.74% | -8.72% | |
| Form 6-K Biodexa Pharmaceuticals For: Mar 27 | SEC filing · Form 6-K | SEC EDGAR | +1.74% | -8.72% | |
| Preliminary Results for the Year Ended 31 December 2025 | Press release | GlobeNewswire | +1.74% | -8.72% | |
| Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group | Press release | GlobeNewswire | -5.13% | -5.00% | |
| ADR Ratio Change | Press release | GlobeNewswire | -2.00% | -8.52% | |
| Form 6-K Biodexa Pharmaceuticals For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | -2.00% | -8.52% | |
| Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients | Press release | GlobeNewswire | — | +4.37% | |
| Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer | Press release | ACCESS Newswire | -3.57% | -7.86% | |
| Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST | Press release | GlobeNewswire | -4.81% | -7.05% | |
| Form 6-K Biodexa Pharmaceuticals For: Feb 04 | SEC filing · Form 6-K | SEC EDGAR | -4.81% | -7.05% | |
| Form 6-K Biodexa Pharmaceuticals For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | +0.83% | +0.41% | |
| Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary | Press release | GlobeNewswire | +0.78% | -1.57% | |
| Form 6-K Biodexa Pharmaceuticals For: Jan 05 | SEC filing · Form 6-K | SEC EDGAR | +0.78% | -1.57% | |
| Biodexa Announces Pricing of $10 Million Public Offering | Press release | GlobeNewswire | +0.91% | -5.68% | |
| Form 6-K Biodexa Pharmaceuticals For: Dec 17 | SEC filing · Form 6-K | SEC EDGAR | +0.91% | -5.68% | |
| Form EFFECT Biodexa Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.91% | -5.68% | |
| Form F-1/A Biodexa Pharmaceuticals | SEC filing · Form F-1 | SEC EDGAR | +4.64% | -18.39% | |
| Form F-1/A Biodexa Pharmaceuticals | SEC filing · Form F-1 | SEC EDGAR | -2.77% | -46.23% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BDRX section they belong to.
Where else BDRX is measured.
BDRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Biodexa Pharmaceuticals plc - American Depositary Shares's median reaction calculated?
Every labeled BDRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 492 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of BDRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BDRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.